Alzprotect

Alzprotect strengthens its Intellectual Property Portfolio for its First-in-Class Clinical Stage Drug Ezeprogind

ALZPROTECT, a biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases announces today that the United States Patent and Trademark Office (USPTO) has recently granted patent number US 10,772,884 concerning the therapeutic uses of its first-in-class clinical stage drug Ezeprogind (AZP2006) in the treatment of tauopathies.

Continue reading

Xerys

XERYS FRANCE

7 rue d’Aguesseau

75008 Paris - France

+33 (0)1 82 52 12 25

FOLLOW-US: